Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to NRG1 (null)
- Target
- null
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Other
01
Overview
Novel transcript, antisense to NRG1" is an annotated long non-coding RNA (lncRNA) expressed from the strand opposite to the Neuregulin 1 (NRG1) locus. It is classified as a a natural antisense transcript (NAT), part of a group of non-coding RNAs widely present in mammalian genomes. NATs generally regulate the expression of their sense (protein-coding) counterparts through diverse mechanisms such as transcriptional interference, RNA masking, double-stranded RNA formation, modulation of mRNA stability, and chromatin remodeling. However, the specific biological role, disease relevance, and clinical utility of this particular NAT remain undetermined due to a lack of direct experimental evidence or characterization in published literature. If you require cross-mapping to entries in drug or target databases, or candidate for therapeutic development, this entity should be flagged as "not a validated drug target" and excluded from downstream workflows.
- Other names
- NRG1 antisense RNAAntisense RNA to Neuregulin 1ENSG00000305898
02
Mechanism of action
null
03
Biological functions
Regulation of gene expression (general to NATs)Post-transcriptional gene silencing or enhancement (potential mechanism)Other (no specific function described for this NAT)
04
Disease associations
Other
Beyond the preview
Go deeper on Novel transcript, antisense to NRG1 (null).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novel transcript, antisense to NRG1 (null).